Gait Disorders in Alzheimer’s Disease and Other Dementias: There is Something in the Way You Walk

Manuel Montero-Odasso\textsuperscript{a,b,}* and George Perry\textsuperscript{c}
\textsuperscript{a}Departments of Medicine (Geriatric Medicine), and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada
\textsuperscript{b}Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, London, ON, Canada
\textsuperscript{c}Department of Biology and UTSA Neuroscience Institute, University of Texas, San Antonio, Texas, USA

Gait impairments are ubiquitous in Alzheimer’s disease (AD) and other dementias. Although the main clinical hallmark of dementia is cognitive impairment and decline [1], motor impairments, such as bradykinesia, extrapyramidal rigidity, and gait disorders, have been commonly described, mostly in late stages [1–3]. However, during the last two decades, large epidemiological studies have shown that gait disorders, particularly slowing gait, may be present at early stages of dementia or may even predict who will be at risk of progressing to dementia [4, 5].

Specifically, in older adults with mild cognitive impairment (MCI), a pre-dementia state, there is a coexistence of specific cognitive deficiencies and gait abnormalities which provides support to the theory that there is a transition period whereby cognitive loss occurs concurrently with gait slowing [6–8]. These motor impairments are not benign. Older adults with MCI are also at higher risk of falling, with double the incidence of their cognitively healthy counterparts. This higher risk of falls has been related to poor attention and executive dysfunction affecting the brain’s gait control [9, 10]. Based on these gait-cognitive interactions, it has been postulated that early gait changes can be used as a motor biomarker to detect individuals who are at risk of progression to AD and non-AD dementias [11–14].

This Journal of Alzheimer’s Disease supplemental issue showcases studies presenting the epidemiology of gait disturbances and cognitive impairment, dissecting specific associations between cognitive domains and quantitative gait parameters, and addressing with advanced neuroimaging techniques the potential mechanisms underlying the gait-cognitive interaction seen before dementia. Also, this issue highlights how to manage mobility impairment in the cognitive impaired by using assistive devices.

From an epidemiological perspective, studies from Jayakody et al. [15] and Toots et al. [16] showed that gait speed is associated with further cognitive decline. These confirmatory studies are adding to our current knowledge about the omnipresent interactions between gait and cognition in older adults. Langeard et al. [17] demonstrated that declines in performance on the “Timed Up and Go”, a motor per-
formance test and proxy of gait performance, in older adults can be mediated by dual-task abilities in cognitive switching. Regarding potential mechanisms underlying gait-cognitive interactions in dementia syndromes, functional and structural brain abnormalities, including atrophy of selected cortical and subcortical areas, white matter disease and amyloid-β deposition burden, and accentuated depletion of neurotransmitters, are considered key provokers of the concurring cognitive and gait impairments, because control of gait and cognitive performance rely on shared brain networks and regions [18–22]. Adding to this knowledge, Allali et al. [23] showed that structural brain volume covariance is associated with gait speed in patients with MCI, confirming earlier findings [21, 24]. Additionally, Dao et al. [25] showed that cerebral amyloid-β deposition is associated with impaired gait speed and lower extremity function.

An emerging approach to address these interactions is using the dual-task gait (DTG) paradigm of walking while performing a concurrent cognitively demanding task as a brain stress test to detect populations at risk. Recently, the DTG test has shown to predict dementia in MCI [13], and this issue includes two studies, Nocera et al. [26] and Cullen et al. [27], that demonstrate the feasibility to perform the DTG test in clinic scenarios. One of these studies also addresses the potential ability of DTG to differentiate cognitive subtyping [27]. Rosso et al. [28] showed the value of DTG to detect individuals at risk of cognitive decline in a cognitive healthy population of older adults. Åhman et al. [29] analyzed associations between DTG performance and AD cerebrospinal fluid biomarkers. This issue presents two studies that showed that motoric cognitive risk syndrome, referring to older individuals that presented both cognitive complaints and slow gait velocity, is associated with frailty [30] and dysfunction of specific quantitative gait parameters [31].

Currently, effective treatments aiming to improve underlying neural mechanisms of high order cognitive functioning are limited to lifestyle interventions, such as physical exercises and cognitive training. These interventions have shown strong signals to improve both cognition and gait in older adults with MCI, mild AD, and other neurodegenerative processes, like Parkinson’s disease [32].

Due to the complexity of cognitive-motor interactions, multiple interventions may be necessary to restore or decelerate the decline of cognition and mobility seen in MCI, AD, and related dementias. Finally, pharmacological and non-pharmacological strategies to improve cognition and gait mobility in seniors with MCI and AD are becoming increasingly available for various therapeutic approaches, including cholinergic enhancement, cognitive remediation, electrical brain stimulation, dual-task training, and physical exercises. The use of assistive devices in older adults that are cognitively impaired can help to improve their mobility and reduce their falls risk, but also can pose a cognitive challenge. Hunter et al. [33, 34] review the effect of learning to use a mobility aid on gait and cognitive demands in AD. Physical activity and mobility can be low in older adults with cognitive impairment, as demonstrated by Taylor et al. [35], who found that older adults with dementia have reduced daily-life activity and impaired daily-life gait when compared to age-sex matched controls.

In sum, this issue of the Journal of Alzheimer’s Disease presents the current state of knowledge on the role of gait disturbances and quantitative gait analyses to be used as a motor biomarker to define subtypes of cognitive profiles and to predict cognitive decline and dementias. Similarly, this issue contributes to the understanding of mechanisms underlying the gait and cognition interaction, and reviews the management of cognitive and motor decline using assistive devices and physical activity and exercise training in AD. To end, we congratulate the cadre of authors for their collective fine work presented which certainly moves forward the field of “gait and cognition” in neurodegeneration and aging.

ACKNOWLEDGMENTS

Dr. Manuel Montero-Odasso’s Program in Gait and Brain Health is supported by grants from the CIHR (MOP 211220, PJT 153100), the Ontario Ministry of Research and Innovation (ER11-08-101), the Ontario Neurodegenerative Disease Research Initiative (OBI 34739), the Canadian Consortium on Neurodegeneration in Aging (FRN CNA 137794), and the Department of Medicine Program of Experimental Medicine Research Award at the University of Western Ontario (POEM768915).

REFERENCES


